| Document Type
|
:
|
BL
|
| Record Number
|
:
|
865634
|
| Title & Author
|
:
|
Communicable diseases of the developing world /\ Anil Kumar Saxena, editor ; with contributions by C.S. Azad [and more].
|
| Publication Statement
|
:
|
Cham, Switzerland :: Springer,, 2018.
|
| Series Statement
|
:
|
Topics in medicinal chemistry,; 29
|
| Page. NO
|
:
|
1 online resource
|
| ISBN
|
:
|
3030086569
|
|
|
:
|
: 3319782533
|
|
|
:
|
: 3319782541
|
|
|
:
|
: 9783030086565
|
|
|
:
|
: 9783319782539
|
|
|
:
|
: 9783319782546
|
|
|
:
|
3319782525
|
|
|
:
|
9783319782522
|
| Notes
|
:
|
Includes index.
|
| Contents
|
:
|
Intro; Preface; Contents; Clinical Management of Ebola Virus Disease: Current and Future Approaches; 1 Introduction; 2 Epidemiology; 2.1 Geographic Spread of Ebola over Time; 2.2 Transmission; 2.3 Surveillance; 2.4 Case Investigation; 2.5 Contact Tracing; 2.6 Control Measures; 3 Pathology; 4 Clinical Presentation and Laboratory Diagnosis; 4.1 Clinical Presentation; 4.2 Laboratory Findings; 5 Clinical Management: Current and Future Approaches; 5.1 Supportive Care; 5.2 Vaccines; 5.2.1 Non-replicating Ebolavirus Vaccines; Inactivated Vaccines; Replicons; DNA Vaccines.
|
|
|
:
|
3 The Main Classes of Anti-HIV Drugs3.1 Viral Enzyme Inhibitors; 3.2 Fusion or Entry Inhibitors; 4 Current State of Anti-HIV Therapy and Recent Studies; 4.1 HIV-1 Reverse Transcriptase (RT) Inhibitors; 4.1.1 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs); Undesired Side Effects of NRTIs; 4.1.2 Non-nucleoside RT Inhibitors (NNRTIs); Undesired Side Effects of NNRTIs; 4.1.3 Nucleotide-Competing RT Inhibitors (NcRTIs); 4.2 HIV-1 Integrase Inhibitors; 4.2.1 Side Effects of Integrase Inhibitors; 4.3 HIV-1 Protease Inhibitors; 4.3.1 Side Effects of Protease Inhibitors.
|
|
|
:
|
4.4 HIV Fusion Inhibitors4.4.1 Side Effects of Fusion Inhibitors; 4.5 Novel Drug Targets: TAR, Tat-Binding Drugs; 5 HAART and Combined Formulations; 6 Current Anti-HIV/AIDS Agent Pipeline; 7 The Future Trends; 7.1 Attempts to Overcome the Latent HIV Infection; 7.2 Natural Products as Potential Anti-HIV Agents; 7.3 Biologicals as Potential Anti-HIV Agents; 7.4 Computer-Aided Drug Discovery of New Anti-HIV Agents; References; Lymphatic Filariasis: Current Status of Elimination Using Chemotherapy and the Need for a Vaccine; 1 Introduction; 2 LF and the Spectrum of Clinical Diseases.
|
|
|
:
|
Ebola rAd5 Replication Defective VaccineOther Adenovirus Vector Vaccines; Subunit Vaccines; Replication-Deficient Ebola Viruses; 5.2.2 Replicating Ebola Viruses Vaccines; Recombinant Vesicular Stomatitis Virus (rVSV); Recombinant Human Parainfluenza Virus Type 3; Rabies Virus; 5.3 Novel Compounds and Drugs; 5.3.1 Antiviral Compounds Undergoing Test in Rodents; FGI-103, FGI-104, and FGI-106; NSC 62914; Small Interfering RNAs (siRNAs); Phosphorodiamidate Morpholino Oligomers (PMOs); Monoclonal Neutralizing Antibodies (NABs); Triple Monoclonal Antibody Cocktail (ZMapp).
|
|
|
:
|
S-Adenosyl-l-Homocysteine Hydrolase Inhibitors5.3.2 Antiviral Compounds Currently Tested in Nonhuman Primate Models of Ebola Infection; Recombinant Human-Activated Protein C (rhAPC); Recombinant Nematode Anticoagulant Protein C2 (rNAPC2); 5.3.3 Other Drugs with Antiviral Activity Against Ebola; Favipiravir; BCX4430; Selective Estrogen Modulator; Lamivudine; Chloroquine; Ribavirin; Brincidofovir; 6 Conclusion; References; Anti-HIV Agents: Current Status and Recent Trends; 1 Introduction; 2 The Biology of HIV; 2.1 Structure and Organization; 2.2 HIV Life Cycle; 2.3 HIV Types.
|
| Abstract
|
:
|
This book reviews the current strategies and challenges for the treatment of bacterial, fungal, parasitic and viral infectious diseases in developing countries. Contributing authors present expert analysis on the transmission, epidemiology, bacteriology, pathogenesis and treatment of Neglected Tropical Bacterial Diseases such as Leprosy, Buruli ulcer, and Trachoma. Particular attention is also given to current antifungal agents, their spectrum of activity, mode of action, limitations, and current challenges in antifungal therapy. The authors explore the medicinal chemistry efforts that gave rise to currently launched drugs and new anti-HIV agents, and they also highlight the latest vaccine and drug developments in the clinical management of the Ebola Virus Disease, ignited by the 2014-2016 outbreak. This work has an interdisciplinary appeal and will engage scholars and professionals in the burden of communicable diseases.
|
| Subject
|
:
|
Communicable diseases-- Developing countries.
|
| Subject
|
:
|
Communicable diseases.
|
| Subject
|
:
|
HEALTH FITNESS-- Diseases-- General.
|
| Subject
|
:
|
MEDICAL-- Clinical Medicine.
|
| Subject
|
:
|
MEDICAL-- Diseases.
|
| Subject
|
:
|
MEDICAL-- Evidence-Based Medicine.
|
| Subject
|
:
|
MEDICAL-- Internal Medicine.
|
| Subject
|
:
|
Developing countries.
|
| Dewey Classification
|
:
|
616.9
|
| LC Classification
|
:
|
RC111
|
| Added Entry
|
:
|
Saxena, Anil Kumar
|